Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning! - 2Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 3Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- 410 Asian Countries Perfect for Solo Female Travelers
- 5Israeli military says it hit dozens of military facilities in Tehran
- Southern Californians, your health insurance costs could rise in 2026
- Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- Israeli strike on Gaza City vehicle kills at least four, report says
- German state railway loss widens, passengers warned of trouble ahead
- At UN climate conference, some activists and scientists want more talk on reforming agriculture
- Which Startup's Innovation Could Reform Medical care?
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
- 3 Italian City Cars That Outsmarted Regulations and Rivals
